Eli Lilly (NYSE: LLY) had a very good year in 2023. Revenue jumped 20% and its stock skyrocketed 59%. The company also claimed the mantle as the world's largest drugmaker by market cap.

Will the momentum continue going forward? Probably. However, it won't be as easy as some might think. Here are four reasons why 2024 could be Eli Lilly's worst year for the rest of this decade.

Type 2 diabetes drug Trulicity ranked as Lilly's top-selling drug last year, raking in sales of more than $7.1 billion. But that total could have been even higher were it not for supply issues.

Continue reading

Source Fool.com